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TNF alpha in the two treatment arms and further study is needed 
to determine the significance of this observation. 
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ANALYSIS OF CD4+CD25 ÷ T REGULATORY CELL SURVIVAL AND 
FUNCTION FOLLOWING IN VITRO AND IN VIVO IRRADIATION 
Zi71~.Me~'~a~, Z.F.; Baez, a7.; Rodeos, M.; ~la~n~ole~ti, ~.;  Levy, R.R 
Microbiology m~d Immmmlogh U~ive'~sit3, of 3/Iiami &'hool of Medid~te, 
Miami, FL. 
Manipulating the host regulatory T cell compartment may be 
useful in BMT strategies for successful engraftment and anti- 
tumor responses. In order to investigate he effect of conditioning 
regimens on host CD4+CD25 + T regulatory cell function prior to 
BMT, highly purified populations of Tregs were produced from 
several mouse strains and exposed to varying levels of gamma irra- 
diation ex vivo. Following treatment, Tregs were co-cultured with 
CD4+CD25 rcsponders, accessory cells, and anti-CD3 mAb. At 
doses as low as 3.0 Gy, Tregs exhibited iminished capacity to 
regulate CD4+ T cell proliferation i~ vit*v. To assess the effect of 
the radiation on Treg survival, purified populations were exposed 
to doses front 3.0Gy to 9.0Gy and assessed by Annexin V staining. 
After 24 hrs., >90% of the Tregs were positive regardless of dose. 
Co-culture with accessory cells and stinmlation with anti-CD3 
during this time period could not rescue these cells from death. 
To examine cell survival following i*z vivo irradiation, splenic 
CD4+CD25 + cells were purified from mice immediately following 
3.0 or 9.0Gy TBI and cultured for 24 hrs. Annexin V staining was 
equivalently as high as in Tregs irradiated ex vivo. Further analysis 
following ex vivo irradiation indicated that apoptotic ells were 
evident between 4 and 8 hours post-exposure. Since >90% of 
Tregs exposed to a dose of 3.0Gy are undergoing apoptosis by 24 
hrs, and these cells did not lose the entirety of their regulato W 
function, four hours after 3.0 Gy, irradiated Tregs were co-cul- 
tured with anti-CD3 and CD25- responding cells to determine the 
kinetics of function post-irradiation. These Tregs failed to exhibit 
any regulatory activity. It may be notable that 24 hrs following 
busulfan treatment (30mg/kg) of B6 mice, CD4+CD25 + Treg ceils 
maintained their ability to regulate CD4 T cell proliferation, in 
total, these observations suggest that immediately following doses 
of ->3.0Gy Treg survival and function appear to be compromised. 
Additionally, alternative conditioning regimens may differentially 
affect he functional capacity of host Treg cells following BMT. 
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THE INFLUENCE OF THE GRAFT MONOCYTES IN THE OUTCOME OF 
ALLOGENEIC BONE MARROW TRANSPLANTATION 
Pe1~teaclo Ara~ha, F.J.; P'igot-ito, A.C.; De Soztza, C.A.; Bo~'ba 
Oliveira, G.; Brito Eicl, K.A.; Zzdli, R.; Lo~:aml-Met~e, L Bm~e Mar- 
7"ow Tra*zsp/a~m~tio*z, State Ut~iz,eJ'si U of Campit~as, Campmas, Sao 
Pazllo, B*'azil. 
Francisco J P Aranha, Afonso C Vigorito, Carmino A De Sousa, 
Gislaine B Oliveira, Katia A Eid, Roberto Zulli, Irene Lorand- 
Metze Bone Marrow Transplantation Unit State University of 
Campinas, SP/Brazil The influence of graft monocytes on GVHD 
has not yet been established in clinical trials.V~te valuated the 
influence of bone marrow graft monocytes aiming, primarily, to
analyse the correlation with aGVHD and cGVHD, and secondar- 
ily with engra~nent and survival. Eligibility criteria age <60 years; 
patients with primary malignant or non-malignant hematological 
disease receiving BM from an HLA-identical sibling. We analyzed 
83 patients. Conditioning was mainly BuCy2 and GVHD prophy- 
laxis CSA-MTX. The median day to reach peripheral leukocytes _> 
0.5x109/1 and platelet count >20x109/1 was 20 (I 1-34) and 18.5 
(10-60) respectively. In univariate analysis, any parameter was cor- 
related with a faster engrafinent. The frequency of a-GV-HD, 
grades 2-4 was 12/83 (i4.5%). In univariate analysis, TNC 
>2.31x108/Kg and CD14+ cells >4.78x106/Kg were correlated 
significantly with lower rates of a-GVHD (p=0.04, p=0.02, respec- 
tively). Furthermore, patients >27 years old and donor gender 
mismatch ad higher rates of aGVHD (p=0.03 and p=0.04, 
respectively). In a nmltivariate analysis, both TNC and age main- 
tain significance for lower risk of a GVHD. The probability was 
3.2% when age < 27 years and TNC infused _> 2.?1 X 108/Kg. A 
higher risk of a-GVHD was found (51.5%) when age > 27 years 
and TNC infused < 2.31 X 108/Kg (P<0.001).The number of 
CD14+ cells showed a correlation with TNC. This interaction 
might be the cause for the loss of significance for monocytes in 
the multivariate analysis. Clinical c GVHD of all grades devel- 
oped in 31/77 (40%) available patients. It was extensive in 20 cases 
and limited in 11 cases. In univariate analyses there was a correla- 
tion between previous a-GVHD and a higher risk of c-GVHD 
(p<0.001). CD14+ cells did not influence c-GVHD. The estimate 
of 6-year overall survival (OS) was 66% (95% CI: 55%-79%). In 
univariate analyses, the absence of a GVHD was correlated with a 
higher survival (p<0.001). Furthermore, there was a trend for a 
better survival in patients receiving more CD34+ cells (p=0.06). 
The CD14 cells had no impact on overall survival. These prelimi- 
nary data suggest that CD14+ cells may have a protective ffect in 
allogeneic BMT. 
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TNF TYPE II RECEPTOR GENOTYPE AFFECTS SOLUBLE RECEPTOR 
LEVELS IN NORMAL SUBJECTS AND ASSOCIATES WITH CHRONIC 
GVHD SEVERITY 
Stark, G. l; DickitlsoJ?, A.M. ~; ffaclesoJ~, G.H.e; Taylor, P.R. "-; Middle- 
to~, P.G. I 1. U'nive~-sity ofNewcastle, Newcastle Hpo~ Tyze, Ul~ited 
KtJagdom; 2. Royal f'tcto*'ia llz/;JwlaJty , Newamle elpo,z Ty,le, U'Mted 
Ki~gdom. 
A single nucleotide polymorphism in the TNF type II recep- 
tor(TNFRII) gene, at codon 196, results in the substitution f 
arginine (R allele) for methionine (M allele). The R allele is 
reported to associate with susceptibility to autoimmune disease 
and donor R allele carriage correlates with acute graft-versus-host 
disease (GVHD) severity after MUD BMT. To investigate the 
functional impact of this polymorphisln, 81 volunteer blood 
donors were genotyped by PCR and SSCP analysis and soluble 
TNFRII (sTNFRII) levels were measured by ELISA. Mean (+/- 
SEM) plasma sTNFRII levels were 1225+/-26 and I063+/-65 for 
individuals caruing at least 1 M allele (M+) and RR homozygotes 
respectively (p=0.02). We examined the impact of this polymor- 
phism on acute and chronic GVHD incidence/severity after non- 
T ceil-depleted sibling BMT. TNFRII 196 M/R genotype was 
determined amongst 106 transplant recipients, 106 donors and 
131 control subjects. R allele frequency amongst recipients, 
donors and controls was 0.28. In univariate analysis there was a 
trend towards increased acute GVHD incidence [odds ratio (OR) 
2.9] amongst R+ recipients (p=0.1). In nmltivariate analysis by 
logistic regression, correcting for established clinical and genetic 
GVHD risk factors, the impact of recipient TNFRII  R+ status 
was reduced (p=0.13). In univariate analysis, donor RR homozy- 
gosity associated with a trend to increased cGVHD incidence (OR 
4.6; p=0.1) and an increased risk of extensive cGVHD (OR 8.5; 
p=0.01). In nmltivariate analysis donor RR homozygosity associat- 
ed with an increased risk of extensive cGVHD (relative risk 11.3; 
p=0.02) but not cGVHD incidence per se. Since sTNFRIIs can 
act as TNF  antagonists, the association between donor RR 
homozygosity and cGVHD may reflect reduced circulating sTN- 
FRII. The role for pharmacological interventions, particularly the 
use of recombinant sTNFRII (Etanercept) requires further inves- 
tigation, but may be influenced by genotype. 
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RAPID ENGRAFTMENT IS ASSOCIATED WITH AN INCREASED INCI- 
DENCE OF GRAFT VS HOST DISEASE (GVHD) IN CHILDREN FOLLOW- 
ING REDUCED-INTENSITY HEMATOPOIETIC STEM CELL TRANSPLAN- 
TATION (RI-HSCT) 
B~wck~le~; L.1; D'lm1"st, R?, K_letzel, ~[.2 i. Golismm Ch//ch'e77 ;" Hos'pi- 
tnl, UJdversitv of Roc,~este1" Medical Celzter, Rochestel; NY," 2. C,~ttctlw~s 
3/iemo~'ial Hospital, Nol-tbwestelw Utlivevsity, Chicago, IL. 
We conducted a retrospective chart review of I9 children who 
had undergone RI-HSCT at Childrens Memorial Hospital over 
B B & 2PI T 99 
Poster  P resentat ions  - Sess ion  I 
the past 2 years. Seven patients were excluded due to non-engraft- 
ment (3), progressive disease necessitating regimen change (2), or 
early death (2). Of  the 12 children included in the study, ages 
ranged from 2 to 22 years (median=I0).  The  male:female 
ratio=7:5. Stenr cell source was PBSC in all cases. Donor type was 
unrelated in 5 cases and related in 7. Reasons for R I -HSCT were: 
ALL(3), NHL(1), ANLL(I),  neuroblastoma (2), SCA(1), 1[3-tha- 
lassemia (1), Sandhoff syndrome(l) and Hyper IgM syndrome (2). 
All patients received conditioning regimens consisting of fludarib- 
ine (30 mg/m2/d X 6), busulfan (1 mg/kg q6 hr IV x 8), and ATG 
(40 mg/kg/d x 4). Cyclosporin (3mg/kg/dose BID)was used as 
GVI tD prophylaxis. Acute GVHD (aGVHD) occurred among 7 
of the 12 patients (incidence=58%); 3 grade Ii, 3 grade IlI, and 1 
grade IV. As expected, aGVHD was more frequent among recipi- 
ents of unrelated transplants; all 5 unrelated RI -HSCT recipients 
developed aGVHD vs. only 2 out of 7 related transplants (p=0.05). 
Complete engraftment was defined as an ANC greater than 500 
and more tllan 75% donor T lymphocytes based on VNTR.  Eight 
patients attained complete ngraftment by 40 days post-transplant 
and 4 patients were much later than 40 days (+108, 127, and 203) 
or not at all (1 long-term stable chimera). Six of the 8 patients 
who engrafted before day 40 developed aGVHD compared to 
only 1 case of aGVHD among the late engrafters (p=0.3). Chronic 
GVHD (cGVHD) occurred among 6 of the 10 evaluable patients 
(incidence=60%); 5 of these occurred among the 6 early engrafters 
vs only 1 cGVHD case among the 3 late engrafters (p=0.24). Of 
the 8 early engrafters, 4 are deceased and 4 are alive with cGVH. 
Among the 4 late engrafters, all are alive; 1 has cGVHD and 1 has 
had progression of Sandhoff syndrome. Although the data did not 
reach statistical significance within this small sample size, the 
results do support an association between the rapidity of engraft- 
ment and the development of acute and chronic GVHD among 
recipients of RI-HSCT. Further studies are warranted to more 
fillly address this issue. 
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ANTI-THYMOCYTE GLOBULIN (ATG), LOW DOSE TBI AND FLUDARA- 
BINE (FLU) CONDITIONING FOR ALLOGENEIC TRANSPLANTATION 
Lrola, L.; Scigliallo, E.; Fl"uchtlmlJz, S.; GJ'ossk~'eutz, C. . 
Non-myeloablative allogeneic PBPC transplant using low dose 
TBI (200 cGy) plus FLU results in lnodest rejection rates. Acute 
and chronic GvHD do not differ substantially from fully ablative 
transplantation. Adding ATG to conditioning produces substan- 
tial host immunosuppression a d in-vivo graft T ceil depletion. 
Twenty-five pts, not eligible for conventional allogeneic SCT by 
virtue of age or co-morbidities, underwent non-myeloablative 
transplantation using ATG 15 mg/kg/day days-4 to- l ,  TBI 200 
cGy on a single fi'action on day -5, fludarabine 301ng/kg/day on 
days-4 to-2. Oral MMF 15 mg/kg/dose Q 12 hrs and CSA 6 
mg/kg/dose Q 12 hrs were started on day-5. Grafts were PBPC 
nmbilized with filgrastim 10 mcg/kg/day. Median age was 53 (30- 
66), diagnoses were 11-NHI,, 6-AML, 3-MM, 1-SAA, 1-PNH 
and 1-MDS. Median CD34+ and CD3+ contents were 
9.05x106/kg and 1.64x108/kg respectively. Three pts (2 with 
VUDs and 1 with a sib donor) received 1 Ag misuratched graft. 
The rest were fully matched. Five pts received VUD grafts. 
Twenty-two pts were evaluable for chimerism: 20 had >98% 
donor chimerism, one 85% and one 23%. Nine pts. relapsed. One 
pt rejected the graft at 180 days. Median hospital stay was 27 days. 
Complications were: GvHD in 6 pts (3 pts had GI-II GvHD of 
skin and liver and 3 pts had GI I I - IV GvHD of liver and gut). 
Three of the pts with GvHD had mismatched grafts. Transplant 
related toxicity was seen in 4 pts and infection in 5 pts. Median 
follow up was 153 days (17-774). CR was seen in 10 pts. Five pts 
remain in CR at 208 to 513 days. One pt relapsed with NHL  after 
a CR of 728 days. Four pts developed significant GvHD and died. 
Of the 25 pts, 16 died (6 relapsed disease, 4 GvHD, 3 infection 
and 3 transplant-related toxicity) and 9 are alive (5 in CR and 4 
with relapsed isease). The addition of ATG to low dose TBI and 
FLU was well tolerated and resulted in 100% donor engraftment. 
As in other series of non-myeloablative transplantation, a high 
rate of relapse was obsmwed. Donor engraftment maybe facilitated 
by the addition of ATG to low dose TBI and FLU conditioning. 
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THE ROLE OF DIGITAL PHOTOGRAPHY IN THE DOCUMENTATION OF 
SKIN GRAFT VERSUS HOST DISEASE 
Mavqz~ese~l, 3/1.; Chauvet, D.; DoJ~ob~e, T.; &lpeT~ata, ft.; Childs, R. 
Ste711 Cell Alloge~zeic Tralz.rplalltatio~z Sectiolz, Hematology Bra~zeh, 
NHLBI, NatioJml hzstitutes of Health, DHHS, Bethesda, MD. 
Graft vs host disease (GVHD) remains a serious and potentially 
life threatening complication of allogeneic stem cell transplanta- 
t ion(SCT). Because a significant proportion of complications 
occur in the first 3 months, patients historically have remained 
geographically attached to the transplant center for 100 days or 
more following SCT. Nonmyeloablative or low intensity allo- 
geneic transplants (NST) are generally well tolerated and associat- 
ed with less to.-dcity than coventional myeloablative transplants. As 
a consequence, patients are frequently sent home as early as 2 
months post-transplant with instructions to taper their GVHD 
prophylaxis, to augment a GVT effect. Transplant recipients are 
at risk for delayed onset GVHD during dais period of immuno- 
suppression withdrawal. Members of the transplant center often 
find themselves managing vague symptoms of acute GVHD com- 
municated over the telephone by primary care physicians or the 
patient hemselves. The diagnosis of liver and GI GVHD is readi- 
ly interpertable based on lab findings or clinical parameters such 
as quantity of diarrhea. In contrast, skin rashes may be variable in 
nature and more difficult to interpret in terms of etiology and 
severity. Inaccurate descriptions of skin changes can lead to erro- 
neous diaguosis of acute or chronic skin GVHD which could have 
a deleterious impact on patient outcome. Furthernmre, the incor- 
rect or over treatment of skin GVHD with immunosuppression 
such as corticosteroids and CSA may result in increased suscepti- 
bility to infectious complications and could potentially delay or 
negate a GWI" effect. This frequently occuring diagnostic dilem- 
ma, has led our intsitute to initiate a trial of monitor ing skin 
abnormalities through the use of digital photographs (DP), when 
significant distance limits the ability of patients to quickly reutrn 
to the transplant center. Patients with access to digital cameras 
and the internet, transmit photographs directly to our transplant 
physicians for timely diagnosis and treatment management. This
system provides a mechanism to diagnose and objectively assess 
acute and chronic skin GVHD allowing for both precise manage- 
nrent as well as a method to document response to therapy. Our 
experience suggests that the use of DP may aid in the diagnosis 
and treatment of skin GVHD, particularly in those patients who 
have been discharged home early after NST. 
HISTOCOM PATIBILITY/ALTERNATIVE STEM 
CELL SOURCES 
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DLA-HAPLOIDENTICAL STEM CELL ALLOGRAFTS AFTER ANTI-CD44 
THERAPY AND NONMYELOABLATIVE CONDITIONING IN A PRECLINI- 
CAL CANINE MODEL 
Ft~kz~da, T.; &orb, R.F.; Gooley, T.; ,%~tos, E.B.; S,md~naiev, B.M. 
CliJlieal Research Divisimz, b;red H~ttcbiJTso~z CaJzcev Research C'e~zte'~; 
Seattle, HZA. 
Background: YVe previously reported that engraftment across a 
dog leukocyte antigen (DLA) haplotype-mismatched barrier can 
be achieved after reduced-intensity conditioning with 450 cGy 
,total body irradiation (TBI) plus post-grafting mycophenolate 
mofetil (MMF) / cyclosporine (CSP) (for 35 days) when anti 
CD44 monoelonal antibody (MAh), $5, is added to the regimen 
pretransplant. Here, we studied the effect of anti-CD44 therapy in 
facilitating engraftment of DLA-haploidentical donor cells after 
nonmyeloablative conditioning with 200 cGy TBI  and prolonged 
postgrafting immunosuppression. Methods:  Thirty recipient dogs 
were administered MAb $5, at a dose of 0.2 mg/kgJday from days 
100 
